Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
Kaida Jiang,1 Lingjiang Li,2 Xueyi Wang,3 Maosheng Fang,4 Jianfei Shi,5 Qiuyun Cao,6 Jincai He,7 Jinan Wang,8 Weihao Tan,8 Cuili Hu8 1Psychiatry Department, Shanghai Mental Health Center, Shanghai, 2Psychiatry Department,The Second Xiangya Hospital, Central South University, Changsha, 3Psychiatry D...
Guardado en:
Autores principales: | Jiang KD, Li LJ, Wang XY, Fang MS, Shi JF, Cao QY, He JC, Wang JN, Tan WH, Hu CL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/59db939c0e694dbaa57b5e90fd50a410 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
por: Wang G, et al.
Publicado: (2018) -
Long-term administration of escitalopram in patients with social anxiety disorder in Japan
por: Asakura S, et al.
Publicado: (2016) -
Preliminary Study on Changes of Sleep EEG Power and Plasma Melatonin in Male Patients With Major Depressive Disorder After 8 Weeks Treatment
por: Xue-Qin Wang, et al.
Publicado: (2021) -
Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation
por: Soraia Silva, et al.
Publicado: (2021) -
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)